Format

Send to

Choose Destination
J Clin Neurosci. 2017 Nov;45:153-154. doi: 10.1016/j.jocn.2017.08.032. Epub 2017 Sep 1.

Riluzole-induced recurrent pancreatitis.

Author information

1
Department of Neurology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal. Electronic address: catarinahfcampos@gmail.com.
2
Department of Neurology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal; Institute of Physiology, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.

Abstract

Riluzole is the only drug approved for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). It is well tolerated, being the most frequent adverse effects asthenia, nausea and reversible increase of liver enzymes levels. Severe adverse effects are extremely rare. We report for the first time, two patients with sporadic limb-onset ALS who developed recurrent acute pancreatitis (AP), with portal vein thrombosis as complication, during treatment with riluzole. We suggest that AP should be considered asa probable rare and severe side effect of treatment with riluzole in patients with ALS. We believe that in patients who develop AP during treatment with riluzole, its withdrawn may prevent recurrent AP and should be discussed with patients.

KEYWORDS:

Amyotrophic Lateral Sclerosis; Pancreatitis; Riluzole; Side-effects

PMID:
28867362
DOI:
10.1016/j.jocn.2017.08.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center